Andere talen AstraZeneca PLC

Aandelen

AZN

GB0009895292

Farmaceutische producten

Beurs gesloten - London S.E. Andere beurzen 17:35:10 15-06-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13.200,00 ^GBX	-1,95%		-4,75%	-4,28%

15/06	Britse beurzen sluiten lager terwijl beleggers vredeskader tussen VS en Iran beoordelen	MT
15/06	Wereldwijde farmareuzen investeren miljarden in versterking Amerikaanse aanwezigheid	RE

Andere talen

15/06	UK Shares End Lower as Investors Assess US-Iran Peace Framework
15/06	Afternoon Meeting: Los mercados cobran su dividendo de paz
15/06	Markets Get Their Peace Dividend
15/06	Global drugmakers invest billions to boost US presence
15/06	Astrazeneca's Ultomiris Receives FDA Priority Review for IgA Nephropathy
15/06	AstraZeneca annonce une bonne nouvelle aux Etats-Unis
15/06	AstraZeneca's Ultomiris wins US FDA priority review in kidney disease
15/06	Feu vert de la FDA pour un test compagnon de Roche
15/06	Astra gets FDA nod; Frasers bids for Accent Group
15/06	AstraZeneca's Ultomiris Gets US FDA Priority Review for IgA Nephropathy
15/06	Bourse : SpaceX brille, Amazon dénonce Anthropic, Saint-Gobain se recentre
15/06	Morning Meeting: ¿Será esta vez la definitiva?
15/06	¿Será esta vez la definitiva?
15/06	Is this finally it?
15/06	AstraZeneca : Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
15/06	AstraZeneca : Truqap approved in US for prostate cancer
15/06	Cette fois, c'est la bonne ?
15/06	China's Harbour BioMed to focus on another patent case after $20 million damages award
15/06	AstraZeneca's Prostate Cancer Treatment Combination Wins US Approval
13/06	Astrazeneca TRUQAP Combination Approves in the US as First and Only Targeted Treatment for PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer
13/06	TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
12/06	AstraZeneca says Truqap combination approved in US for prostate cancer
12/06	AstraZeneca Says FDA Approves Truqap Combination for PTEN-Deficient Prostate Cancer
12/06	AstraZeneca's Drug Combination for Prostate Cancer Treatment Gets U.S. Approval
12/06	Roche erhält US-Zulassung für Begleitdiagnostikum bei Prostatakrebs